30 October 1998
Med Sci Monit 1998; 4(6): RA1104-1110 :: ID: 501946
Cardiovascular diseases are main, potentially lethal, complications of renal diseases. When using cardiovascular drugs, one should take into consideration the following factors:
- the close cause-effect relationship between cardiac and renal diseases.
- polymorphism of cardiologic complications.
- multiple 'nephrogenic' factors that determine the occurrence of cardiologic complications and their resistance towards standard cardiologic agents. These factors include: hyperkaliemia and hypokaliemia, hypercalcemia and hypocalcemia, hypomagnesemia, metabolic acidosis;
- nephrogenic anemia, secondary hyperparathyroidism, lipid disturbances, hypoproteinemia, coexistent liver damage;
- modifying effect of uremia and dialysis therapy on the pharmacodynamics of cardiologic drugs.Since an ideal cardiological agent is unavailable and the correlation between renal elimination of cardiac drugs and the rate of glomerular filtration remains approximate, cardiac drug doses should be chosen individually, depending on the patients hemodynamic condition, degree of renal failure, evidence of drug cumulation and its blood concentration level. One of the tables is attached, presents cardiac drugs which may be given to patients with renal failure following maintenance dose modification. It is also worth mentioning that cardiac drugs should be administered in full saturating doses in patients with renal failure, and maintenance doses should be modified in such a way as to ensure a stable drug blood level. This may be achieved by reduction of single doses instead of time gap prolongation between standard doses. This study presents a review of cardiovascular drugs taking into consideration their potential benefits as well as potential renal damage with special reference towards: inotropic drugs, antiarrhythmic drugs, adenosine (Adenocor), ACE inhibitors, nitrates, antiplatelet and fibrinolytic drugs, as well as new cardioprotective agents. Presented here, are case reports of successfully treated severe cardiovascular complications in patients with renal failure.
Keywords: renal failure, Dialysis, Cardiovascular Agents
01 November 2023 : EditorialEditorial: Factors Driving New Variants of SARS-CoV-2, Immune Escape, and Resistance to Antiviral Treatments as the End of the COVID-19 Pandemic is Declared
Med Sci Monit 2023; 29:e942960
28 Nov 2023 : Clinical ResearchImpact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and ...
Med Sci Monit In Press; DOI: 10.12659/MSM.942122
28 Nov 2023 : Clinical ResearchLong-Term Outcomes of Decompression and Grafting in Acute Pathological Proximal Femur Fractures in Children...
Med Sci Monit In Press; DOI: 10.12659/MSM.943031
27 Nov 2023 : Clinical ResearchComparison of Outcomes from Emergency Admissions to a Major Trauma Center in Turkey of 1646 Elderly Patient...
Med Sci Monit In Press; DOI: 10.12659/MSM.942916
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical ResearchPrevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292